Report cover image

Vitiligo Market, Size, Share, Global Forecast 2022-2027, Industry Trends, Impact of COVID-19, Growth, Opportunity Company Analysis

Publisher Renub Research
Published Jan 01, 2022
Length 200 Pages
SKU # RNBR16906321

Description

Vitiligo Market, Size, Share, Global Forecast 2022-2027, Industry Trends, Impact of COVID-19, Growth, Opportunity Company Analysis

The Global Vitiligo Market is anticipated to attain US$ 4.3 Billion by 2027. In general, vitiligo is an unpredictable skin disease that causes a gradual loss of skin colour and overlying hair on different body parts. Moreover, contrary to popular belief, vitiligo is not a cosmetic disorder but a systemic disease affecting the most significant body organ and other vital systems. Besides, vitiligo is a life-long condition, and it’s unlikely that one will ever be completely free of it. Further, the actual cause for vitiligo is typically unknown; it is believed to be caused due to genetic susceptivity activated by emotional distress, environmental factors, certain chemicals or toxins, altered cellular environment, physical skin damage, impaired digestion or hormonal changes.

Vitiligo Industry Growth Rate Affected by COVID-19 Pandemic:

In 2020, the vitiligo industry growth rate was affected by the COVID-19 pandemic. As the world haphazardly endeavoured to defeat a deadly virus, many vitiligo projects worldwide like in China, Germany, South Korea and the United States were put on hold. However, many promising drugs have yet continued to tick along in late-stage trials and approval discussions, accounting for a slow growth rate in the industry. According to Renub Research, Global Vitiligo Market Size has reached US$ 3.5 Billion in 2021 post gradual recovery from the pandemic.

Pipe Line Drugs at Late Stages Provide Ray of Hope to Deal with Vitiligo Disorder:

Currently, there’s neither a cure for vitiligo nor a universally accepted method for limiting the spread of the disease. Although visible symptoms are temporarily reversible with a range of treatments, their combination works far better than monotherapy. Presently, there are numerous Vitiligo Pipe Line Drugs in the industry, such as ARN-4079, ATI-502, AX-1602, BOS-475, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib and VLRX-001 available. Further, the choice of drugs is often characterized by trial and error. Apart from the drugs, patients also try to restore pigmentation, camouflage the white patches, or destroy the remaining colour to have all-white skin to deal with vitiligo disorder.

Global Vitiligo Market registered a CAGR of 3.5% from 2021 to 2027:

Remarkably, vitiligo signs and activity vary considerably from person to person, and it is usually progressive. In numerous cases, the disease onset is before 20 years and is developed, especially in the first 10–20 years. However, the good news is that vitiligo, upsetting as it can be to those living with it, is neither life-threatening nor contagious. Additionally, the proper treatment protocol may effectively put it under control and reduce the appearance of white lesions. The market drivers such as increasing incidence of vitiligo disorder, changing lifestyle, rising awareness among the individuals and availability of appropriate treatment are further expected to expand the vitiligo market globally.

United States has the Largest Market for Vitiligo

Our report covers countries like the United States, India, China, Japan, Germany, United Kingdom, Italy, and France constituting the vitiligo market. Globally, the United States market contributes for the largest market share for Vitiligo Market and dominates the overall market. Notwithstanding, increasing incidence of skin disorders such as vitiligo, increasing adoption rate of phototherapy treatment and rising investment in healthcare facilities are attributed to the growth factors.

India also holds a significant largest market share for vitiligo due to significant market players, increasing investment in research and development activities, and undergoing severe clinical trials. The United Kingdom is anticipated to expand the vitiligo market due to advancing government funding, fostering the adoption rate of new technology and drugs, and increasing medical tourism in its states.

Companies Working in Vitiligo Industry:

Recently the top key players in the Global Vitiligo Market are Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals Ltd, Astellas pharma inc and Baxter International Inc. In addition, for all the optimism surrounding vitiligo therapies from these big pharma companies, their side-effects and short-lived therapeutic effect is of great concern. The companies may further hold more hope for vitiligo patients and are most attractive for investors in the life sciences industry in the coming years.

Renub Research latest report “Vitiligo Market, Global Forecast byCountry (United States, United Kingdom, France, Germany, Italy, India, China and Japan), Vitiligo Pipe Line Drugs (ARN-4079, ATI-502, AX-1602, BOS-475, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib and VLRX-001), Companies (Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals Ltd, Astellas pharma inc and Baxter International Inc.)” provides a detailed analysis of Global Vitiligo Industry.

Country – Vitiligo Patient Numbers & Market has been covered from 8 viewpoints:

1. United States
2. United Kingdom
3. France
4. Germany
5. Italy
6. India
7. China
8. Japan

Vitiligo Pipe Line Drugs market has been covered from 10 viewpoints:

1. ARN-4079
2. ATI-502
3. AX-1602
4. BOS-475
5. CCP-070
6. Cerdulatinib (RVT-502)
7. HuABC-2
8. Abatacept
9. Topical Ruxolitinib
10. VLRX-001

Company Insight:

• Overview
• Company Initiatives
• Financial Insight

Companies Covered:

1. Incyte Corporation
2. Bristol-Myers Squibb
3. Clinuvel Pharmaceuticals Ltd
4. Astellas pharma inc
5. Baxter International Inc.

Table of Contents

200 Pages
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Vitiligo Market & Patient Numbers
5.1 Vitiligo Market
5.2 Vitiligo Patients Numbers
6. Vitiligo Share – Market & Patients
6.1 Market Share
6.1.1 By Vitiligo Type
6.1.2 By Treatment Type
6.1.3 By Epidemiology Treatments
6.1.4 By End User
6.1.5 By Country Vitiligo Market Share
6.2 Volume Share
6.2.1 By Country Vitiligo Patient Numbers Share
7. Diseases Type – Global Vitiligo Market
7.1 Segmental
7.2 Non Segmental
8. Treatment Type - Global Vitiligo Market
8.1 Topical Treatments
8.2 Light Therapy
8.3 Surgical Procedures
8.4 Others
9. Epidemiology Treatments - Global Vitiligo Treatment Types Market
9.1 Topical Treatments
9.2 Light Therapy
9.3 Surgical Procedures
9.4 Others
10. End User – Global Vitiligo Market
10.1 Hospitals
10.2 Ambulatory Clinics
10.3 Others
11. Country – Vitiligo Market & Patient Numbers
11.1 United States
11.1.1 Vitiligo Market
11.1.2 Vitiligo Patient Numbers
11.2 United Kingdom
11.2.1 Vitiligo Market
11.2.2 Vitiligo Patient Numbers
11.3 France
11.3.1 Vitiligo Market
11.3.2 Vitiligo Patient Numbers
11.4 Germany
11.4.1 Vitiligo Market
11.4.2 Vitiligo Patient Numbers
11.5 Italy
11.5.1 Vitiligo Market
11.5.2 Vitiligo Patient Numbers
11.6 India
11.6.1 Vitiligo Market
11.6.2 Vitiligo Patient Numbers
11.7 China
11.7.1 Vitiligo Market
11.7.2 Vitiligo Patient Numbers
11.8 Japan
11.8.1 Vitiligo Market
11.8.2 Vitiligo Patient Numbers
12. Vitiligo Pipe Line Drugs
12.1 ARN-4079
12.2 ATI-502
12.3 AX-1602
12.4 BOS-475
12.5 CCP-070
12.6 Cerdulatinib (RVT-502)
12.7 HuABC-2
12.8 Abatacept
12.9 Topical Ruxolitinib
12.10 VLRX-001
13. Clinical Study of Vitiligo Market
14. Porters Five Forces
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes
15. Company Analysis
15.1 Incyte Corporation
15.1.1 Company Overview
15.1.2 Initiatives
15.1.3 Financial Insight
15.2 Bristol-Myers Squibb
15.2.1 Company Overview
15.2.2 Initiatives
15.2.3 Financial Insight
15.3 Clinuvel Pharmaceuticals Ltd
15.3.1 Company Overview
15.3.2 Company Initiatives
15.3.3 Financial Insight
15.4 Astellas pharma inc
15.4.1 Company Overview
15.4.2 Company Initiatives
15.4.3 Financial Insight
15.5 Baxter International Inc.
15.5.1 Company Overview
15.5.2 Company Initiatives
15.5.3 Financial Insight
List Of Figures:
Figure-01: Global Vitiligo Market (Million US$), 2016 – 2021
Figure-02: Global – Forecast for Vitiligo Market (Million US$), 2022 – 2027
Figure-03: Global Vitiligo Patients Population Volume (Thousand), 2016 – 2021
Figure-04: Global – Forecast for Vitiligo Patients Population Volume (Thousand), 2022 – 2027
Figure-05: Diseases Type – Segmental Market (Million US$), 2016 – 2021
Figure-06: Diseases Type – Forecast for Segmental Market (Million US$), 2022 – 2027
Figure-07: Diseases Type – Non Segmental Market (Million US$), 2016 – 2021
Figure-08: Diseases Type – Forecast for Non Segmental Market (Million US$), 2022 – 2027
Figure-09: Treatment Type – Topical Treatments Market (Million US$), 2016 – 2021
Figure-10: Treatment Type – Forecast for Topical Treatments Market (Million US$), 2022 – 2027
Figure-11: Treatment Type – Light Therapy Market (Million US$), 2016 – 2021
Figure-12: Treatment Type – Forecast for Light Therapy Market (Million US$), 2022 – 2027
Figure-13: Treatment Type – Surgical Procedures Market (Million US$), 2016 – 2021
Figure-14: Treatment Type – Forecast for Surgical Procedures Market (Million US$), 2022 – 2027
Figure-15: Treatment Type – Others Market (Million US$), 2016 – 2021
Figure-16: Treatment Type – Forecast for Others Market (Million US$), 2022 – 2027
Figure-17: Epidemiology Treatments – Topical Treatments Market (Million US$), 2016 – 2021
Figure-18: Epidemiology Treatments – Forecast for Topical Treatments Market (Million US$), 2022 – 2027
Figure-19: Epidemiology Treatments – Light Therapy Market (Million US$), 2016 – 2021
Figure-20: Epidemiology Treatments – Forecast for Light Therapy Market (Million US$), 2022 – 2027
Figure-21: Epidemiology Treatments – Surgical Procedures Market (Million US$), 2016 – 2021
Figure-22: Epidemiology Treatments – Forecast for Surgical Procedures Market (Million US$), 2022 – 2027
Figure-23: Epidemiology Treatments – Others Market (Million US$), 2016 – 2021
Figure-24: Epidemiology Treatments – Forecast for Others Market (Million US$), 2022 – 2027
Figure-25: End User – Hospitals Market (Million US$), 2016 – 2021
Figure-26: End User – Forecast for Hospitals Market (Million US$), 2022 – 2027
Figure-27: End User – Ambulatory Clinics Market (Million US$), 2016 – 2021
Figure-28: End User – Forecast for Ambulatory Clinics Market (Million US$), 2022 – 2027
Figure-29: End User – Others Market (Million US$), 2016 – 2021
Figure-30: End User – Forecast for Others Market (Million US$), 2022 – 2027
Figure-31: United States – Vitiligo Market (Million US$), 2016 – 2021
Figure-32: United States – Forecast for Vitiligo Market (Million US$), 2022 – 2027
Figure-33: United States – Vitiligo Patients Population Volume (Thousand), 2016 – 2021
Figure-34: United States – Forecast for Vitiligo Patients Population Volume (Thousand), 2022 – 2027
Figure-35: United Kingdom – Vitiligo Market (Million US$), 2016 – 2021
Figure-36: United Kingdom – Forecast for Vitiligo Market (Million US$), 2022 – 2027
Figure-37: United Kingdom – Vitiligo Patients Population Volume (Thousand), 2016 – 2021
Figure-38: United Kingdom – Forecast for Vitiligo Patients Population Volume (Thousand), 2022 – 2027
Figure-39: France – Vitiligo Market (Million US$), 2016 – 2021
Figure-40: France – Forecast for Vitiligo Market (Million US$), 2022 – 2027
Figure-41: France – Vitiligo Patients Population Volume (Thousand), 2016 – 2021
Figure-42: France – Forecast for Vitiligo Patients Population Volume (Thousand), 2022 – 2027
Figure-43: Germany – Vitiligo Market (Million US$), 2016 – 2021
Figure-44: Germany – Forecast for Vitiligo Market (Million US$), 2022 – 2027
Figure-45: Germany – Vitiligo Patients Population Volume (Thousand), 2016 – 2021
Figure-46: Germany – Forecast for Vitiligo Patients Population Volume (Thousand), 2022 – 2027
Figure-47: Italy – Vitiligo Market (Million US$), 2016 – 2021
Figure-48: Italy – Forecast for Vitiligo Market (Million US$), 2022 – 2027
Figure-49: Italy – Vitiligo Patients Population Volume (Thousand), 2016 – 2021
Figure-50: Italy – Forecast for Vitiligo Patients Population Volume (Thousand), 2022 – 2027
Figure-51: India – Vitiligo Market (Million US$), 2016 – 2021
Figure-52: India – Forecast for Vitiligo Market (Million US$), 2022 – 2027
Figure-53: India – Vitiligo Patients Population Volume (Thousand), 2016 – 2021
Figure-54: India – Forecast for Vitiligo Patients Population Volume (Thousand), 2022 – 2027
Figure-55: China – Vitiligo Market (Million US$), 2016 – 2021
Figure-56: China – Forecast for Vitiligo Market (Million US$), 2022 – 2027
Figure-57: China – Vitiligo Patients Population Volume (Thousand), 2016 – 2021
Figure-58: China – Forecast for Vitiligo Patients Population Volume (Thousand), 2022 – 2027
Figure-59: Japan – Vitiligo Market (Million US$), 2016 – 2021
Figure-60: Japan – Forecast for Vitiligo Market (Million US$), 2022 – 2027
Figure-61: Japan – Vitiligo Patients Population Volume (Thousand), 2016 – 2021
Figure-62: Japan – Forecast for Vitiligo Patients Population Volume (Thousand), 2022 – 2027
Figure-63: Vitiligo Pipe Line Drug – ARN-4079 Status (2018)
Figure-64: Vitiligo Pipe Line Drug – ATI-502 Status (2018)
Figure-65: Vitiligo Pipe Line Drug – AX-1602 Status (2018)
Figure-66: Vitiligo Pipe Line Drug – BOS-475 Status (2018)
Figure-67: Vitiligo Pipe Line Drug – CCP-070 Status (2018)
Figure-68: Vitiligo Pipe Line Drug – Cerdulatinib (RVT-502) Status (2018)
Figure-69: Vitiligo Pipe Line Drug – HuABC-2 Status (2018)
Figure-70: Vitiligo Pipe Line Drug – Abatacept Status (2018)
Figure-71: Vitiligo Pipe Line Drug – Topical Ruxolitinib Status (2018)
Figure-72: Vitiligo Pipe Line Drug – VLRX-001 Status (2018)
Figure-73: Incyte Corporation – Global Sales (Million US$), 2016 – 2021
Figure-74: Incyte Corporation – Forecast for Global Sales (Million US$), 2022 – 2027
Figure-75: Bristol-Myers Squibb – Global Sales (Million US$), 2016 – 2021
Figure-76: Bristol-Myers Squibb – Forecast for Global Sales (Million US$), 2022 – 2027
Figure-77: Clinuvel Pharmaceuticals Limited – Global Sales (Thousand US$), 2016 – 2021
Figure-78: Clinuvel Pharmaceuticals Limited – Forecast for Global Sales (Thousand US$), 2022 – 2027
Figure-79: Astellas pharma Inc. – Global Sales (Thousand US$), 2016 – 2021
Figure-80: Astellas pharma Inc. – Forecast for Global Sales (Thousand US$), 2022 – 2027
Figure-81: Baxter International Inc. – Global Sales (Thousand US$), 2016 – 2021
Figure-82: Baxter International Inc. – Forecast for Global Sales (Thousand US$), 2022 – 2027
List Of Tables:
Table-01: Global – Vitiligo Market Share by Vitiligo Type (Percent), 2016 – 2021
Table-02: Global – Forecast for Vitiligo Market Share by Vitiligo Type (Percent), 2022 – 2027
Table-03: Global – Vitiligo Market Share by Treatment Type (Percent), 2016 – 2021
Table-04: Global – Forecast for Vitiligo Market Share by Treatment Type (Percent), 2022 – 2027
Table-05: Global – Vitiligo Market Share by Epidemiology Treatments (Percent), 2016 – 2021
Table-06: Global – Forecast for Vitiligo Market Share by Epidemiology Treatments (Percent), 2022 – 2027
Table-07: Global – Vitiligo Market Share by End-User (Percent), 2016 – 2021
Table-08: Global – Forecast for Vitiligo Market Share by End-User (Percent), 2022 – 2027
Table-09: Global – Vitiligo Market Share by Country (Percent), 2016 – 2021
Table-10: Global – Forecast for Vitiligo Market Share by Country (Percent), 2022 – 2027
Table-11: Global – Vitiligo Patient Numbers Share by Country (Percent), 2016 – 2021
Table-12: Global – Forecast for Vitiligo Patient Numbers Share by Country (Percent), 2022 – 2027
Table-13: Global – Vitiligo Market Clinical Study, 2018

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us